Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

NCT02045797 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02045797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02045797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
March 24, 2014
Completion date
June 29, 2015
Enrollment
126 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

infections, bacterial